you are here:

Celestial Biolabs Ltd.

BSE: 532871 | NSE: CELESTIAL | Series: NA | ISIN: INE221I01017 | SECTOR: Pharmaceuticals

BSE Live

Mar 11, 16:00
2.02 0.00 (0.00%)
No Data Available
  • Prev. Close


  • Open Price


  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    2.02 (1876)

Celestial Biolabs is not traded on BSE in the last 30 days

NSE Live

Mar 11, 15:32
1.75 0.00 (0.00%)
No Data Available
  • Prev. Close


  • Open Price


  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

Celestial Biolabs is not traded on NSE in the last 30 days

Annual Report

For Year :
2016 2015 2014 2013 2012 2011 2010

Chairman's Speech


Dear Members

Collaborative Research is the key factor in bringing quality and effective biopharmaceutical range of products. Initiative towards Biopharma product development that is process driven, time taking and expensive is continuing with limited resources. New and Innovative products shall always create demand and your company shall be benefitted. Ultimately, our R&D initiatives have given us two research products like Cadalmin and Biovita. 4 New molecules in peptide and 5 products in Enzymes are in advance stage of development. Anti diabetes product fully validated and clinically tested is ready to be launched shortly At this stage, Now, we have the range of products including anti collastral and anti obesity products and making suitable promotional strategy to create consumer interest and demand.


Bio vita and Cadalmin GAe have already made an established mark in the market. Herbal and Enzyme formulations can also be marketed worldwide by using online platform along with off line present marketing activities, We are moving in synergy by improving our supply chain and also introducing new control measures. We have already started advertising our Lead research product called Cadalmin, Our effort is continuing to establish OTC market for all our products. We shall spread our domestic marketing in 15 states from April 2017 onwards.


Biopharmaceutical Industry scenario is very good but we are addressing with great care to revamp our business model. Pharma industry shall be able to keep the pace with the good quality products as there is always demand for such quality pharma products. Our most of the products are very effective and we are making every effort to meet the demand. We are developing effective supply chain management by introducing new CSA and stockiest at different places. We are also introducing incentive scheme to stockiest sales person in order to increase the volume of sales

The biopharmaceutical market is highly competitive. In order to have a competitive edge, our facility at Biotech park is an integrated facility clubbed with extremely good facility of R&D where product development of innovative project shall be the key factor. We will continue to pursue our R&D initiative in peptide, Enzymes and protein and proceed with manufacturing of these products at new facility. Project at SEZ, Biotech park. This will provide us an opportunity to market our products in Domestic and overseas market.


All efforts are in place towards brand building and advertising to handle OTC marketing, We are able to build better volume by Strengthening the manufacturing, marketing and distribution We are in the process of meeting WHO stamping on the premier products and that shall provide us an opportunity to market our products in African and south East Asian countries attracting premier pricing.. Reaching everywhere through C&F and distributors is an difficult proposition and online sales will take us at every corner of India. Feed supplement to cattle’s, poultry and fisheries is an major task to us and celestial is continuously trying to improve the reach and increase the range of feed supplements in order to spread the sale of feed supplements across India.

Human Resource

Human power is an most recognized tool to increase productivity. Effective and Quality manpower and their retention is always an challenging task and addressing this task carefully shall increase the productivity. We have taken very careful steps to retain only quality, dedicated and efficient staff. Training courses and sending them to various seminars and symposium shall also be our priority and thus we will ensure professional skill development. We have taken a Person with Company secretary and chartered accountancy qualification and also are in the process of recruiting Business development and Research and developmental professionals


Research cost is becoming more and more day by day and it needs an optimization effort .Collaborative research is essential for a company like us so that we can always fulfill our research objective most economically and effectively. We are also developing collaborations with CSIR and ICAR and ICMR institutions to develop the Biotech products. Collaborative research projects with these premier research organization shall provide a competitive edge and also increase our learning graph having association with very experienced Research scientists of these prominent institutions.. We are also installing software at each C&F in all the states to make our monitoring and control more We are making every effort to complete the remaining work at city and Biotech park facility so that production, supply chain can be improved in order to increase the business volume. CMFRI Kochin association has given us Cadalmin, a great product. Cadalmin efficacy is so high that people suffering from arthritis are getting tremendous relief. Further we are moving to launch a much needed research product to treat diabetes.

Value to the shareholders

We have always been instrumental in increasing share holders value. Shareholders are very important to us. We always keep shares holders interest on priority and would like to ensure all our shares holders shall be benefitted immensely. . Increasing the investor wealth is our top priority and we will make rapid progress towards achieving our objective once our capital project is completed. We always address any complaint by shareholders very promptly in order to increase share holders value, we are in the process of reorganizing our research and manufacturing.

Corporate Social responsibility

Society in general needs to get benefit out of industries. We are providing medicines on a very concessional rate to under privileged and handicap people who cannot afford to buy the expensive medicines. This distribution is being done in villages through AWAKE RESEARCH and SERVICE FOUNDATION, a voluntary and social organization. We are also making effort to buy herbal raw material from farmers driven source directly by giving value to farmers and also ensuring good quality of raw material. There is very good response from farmers to work on contract farming to grow medicinal plants and shall be moving shortly to have such agreement with farmers cooperative society


While sincerely acknowledging the valuable input by our esteem shareholders, we thank all our shareholders, stake holders, staff and business associates for their continued support and look forward to your valuable advice to achieve our objective at regular interval

Dr A.N. Singh